Atea Pharmaceuticals Inc. (NASDAQ:AVIR) trading with a subtraction of -$0.82 to $40.88 on Thursday, a downside of -1.97 percent. An average of 1,863,710 shares of common stock have been traded in the last five days. There was a fall of -$0.23 in the past week. The last 20 days have seen an average of 3,160,762 shares traded, while the 50-day average volume stands at 1,994,793.
AVIR stock has increased by 50.43% in the last month. The company shares reached their 1-month lowest point of $25.56 on 09/15/21. Shares of the company touched a low of $18.72 and a high of $94.17 in 52 weeks. It has reached a new high 16 times so far this year and lost -0.19% or -$0.98 in price. In spite of this, the price is down -56.59% from the 52-week high.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
Atea Pharmaceuticals Inc. (AVIR) has a trailing price-to-earnings (P/E) ratio of 105.57, which compares with the 34.65 for the broader industry and 32.79 for the sector. In the last five years, Atea Pharmaceuticals Inc.’s PE ratio has ranged between 393.61 and 54.95. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 20.20, the price-to-book (PB) ratio at 5.77.
The quick ratio of Atea Pharmaceuticals Inc. for the three months ended June 29 was 3.20, and the current ratio was 3.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Atea Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -22.64%. Its gross profit as reported stood at $59.66 million compared to revenue of $48.63 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Atea Pharmaceuticals Inc.’s return on assets was 5.30%. For the broader industry, ROE averaged -68.79 over the past year.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $1.54 million in the quarter, while revenues of $30.71 million were grew 100.0%. The analyst consensus anticipated Atea Pharmaceuticals Inc.’s latest quarter earnings to come in at $0 per share, but it turned out to be $0.02,. For the quarter, EBITDA amounted to $8.7 million. Shareholders own equity worth $82.78 million.
From a technical analysis perspective, let’s take a brief look at Atea Pharmaceuticals Inc. (AVIR) price momentum. RSI 9-day as of the close on 13 October was 61.50%, suggesting the stock is Neutral, with historical volatility in this time frame at 73.96%.
As of today, AVIR’s price is $39.96 -0.56% or -$0.23 from its 5-day moving average. AVIR is currently trading +50.39% higher than its 20-day SMA and +97.29% higher than its 100-day SMA. However, the stock’s current price level is +53.44% above the SMA50 and +3.71% above the SMA200.
The stochastic %K and %D were 59.90% and 57.72%, respectively, and the average true range (ATR) was 3.47. With the 14-day stochastic at 62.52% and the average true range at 3.27, the RSI (14) stands at 62.23%. The stock has reached -0.55 on the 9-day MACD Oscillator while the 14-day reading was at 1.53.
Morgan Stanley downgraded Atea Pharmaceuticals Inc. (NASDAQ: AVIR) to a an Equal-weight rating in its most recent analyst report. Previously, the stock was rated as a an Overweight.The consensus rating for Atea Pharmaceuticals Inc. (AVIR) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AVIR, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.
What is AVIR’s price target for the next 12 months?
Analysts predict a range of price targets between $55.00 and $60.00, with a median target of $56.00. Taking a look at these predictions, the average price target given by analysts for Atea Pharmaceuticals Inc. (AVIR) stock is $57.00.